NovaBay Pharmaceuticals (NBY)
(Real Time Quote from BATS)
$0.08 USD
0.00 (3.49%)
Updated Apr 25, 2024 10:52 AM ET
2-Buy of 5 2
F Value A Growth A Momentum B VGM
Income Statements
Fiscal Year end for NovaBay Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 15 | 14 | 8 | 10 | 7 |
Cost Of Goods | 7 | 7 | 3 | 4 | 2 |
Gross Profit | 8 | 8 | 6 | 6 | 5 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 22 | 15 | 12 | 14 |
Income After Depreciation & Amortization | -8 | -14 | -9 | -6 | -9 |
Non-Operating Income | -2 | 4 | 3 | -5 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -10 | -11 | -6 | -11 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | -11 | -6 | -11 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | -11 | -6 | -11 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -7 | -9 | -6 | -9 |
Depreciation & Amortization (Cash Flow) | 4 | 7 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -14 | -9 | -6 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.22 | 1.61 | 1.25 | 1.00 | 0.62 |
Diluted EPS Before Non-Recurring Items | -3.35 | -10.10 | -5.24 | -10.84 | -16.78 |
Diluted Net EPS (GAAP) | -3.96 | -10.10 | -5.24 | -10.84 | -16.78 |
Fiscal Year end for NovaBay Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.73 | 3.27 | 4.61 | 3.12 |
Cost Of Goods | NA | 1.91 | 1.43 | 2.30 | 1.19 |
Gross Profit | NA | 1.81 | 1.84 | 2.31 | 1.94 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.20 | 2.95 | 3.66 | 3.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.39 | -1.11 | -1.35 | -1.73 |
Non-Operating Income | NA | -0.72 | -0.64 | -0.68 | -0.01 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -4.11 | -1.76 | -2.04 | -1.74 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.11 | -1.76 | -2.04 | -1.74 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.11 | -1.76 | -2.04 | -1.74 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 6.90 | 4.69 | 3.18 | 2.04 |
Diluted EPS Before Non-Recurring Items | NA | -0.95 | -0.37 | -1.27 | -0.85 |
Diluted Net EPS (GAAP) | NA | -1.47 | -0.37 | -1.27 | -0.85 |